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Background: The Aβ peptide that accumulates in Alzheimer’s disease (AD) is derived from amyloid precursor
protein (APP) following proteolysis by β- and γ-secretases. Substantial evidence indicates that alterations in APP
trafficking within the secretory and endocytic pathways directly impact the interaction of APP with these secretases
and subsequent Aβ production. Various members of the low-density lipoprotein receptor (LDLR) family have been
reported to play a role in APP trafficking and processing and are important risk factors in AD. We recently
characterized a distinct member of the LDLR family called LDLR-related protein 10 (LRP10) that shuttles between
the trans-Golgi Network (TGN), plasma membrane (PM), and endosomes. Here we investigated whether LRP10
participates in APP intracellular trafficking and Aβ production.
Results: In this report, we provide evidence that LRP10 is a functional APP receptor involved in APP trafficking and
processing. LRP10 interacts directly with the ectodomain of APP and colocalizes with APP at the TGN. Increased
expression of LRP10 in human neuroblastoma SH-SY5Y cells induces the accumulation of mature APP in the Golgi
and reduces its presence at the cell surface and its processing into Aβ, while knockdown of LRP10 expression
increases Aβ production. Mutations of key motifs responsible for the recycling of LRP10 to the TGN results in the
aberrant redistribution of APP with LRP10 to early endosomes and a concomitant increase in APP β-cleavage into
Aβ. Furthermore, expression of LRP10 is significantly lower in the post-mortem brain tissues of AD patients,
supporting a possible role for LRP10 in AD.
Conclusions: The present study identified LRP10 as a novel APP sorting receptor that protects APP from
amyloidogenic processing, suggesting that a decrease in LRP10 function may contribute to the pathogenesis of
Alzheimer’s disease.
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Figure 1 LRP10 interacts with APP. (A) In vivo interaction of LRP10-
HA and GFP-APP695 proteins. Lysates of HEK cells transfected with HA-
tagged LRP10 and GFP or GFP-tagged APP were immunoprecipitated
with anti-HA and then immunoblotted with anti-HA or anti-GFP
antibody to detect LRP10 and GFP, respectively. (B) LRP10-HA interacts
with endogenous APP. Lysates of HEK cells transfected with pcDNA3-
HA or LRP10-HA were immunoprecipitated with anti-APP antibody
and then immunoblotted with anti-HA antibody.
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Amyloid-β (Aβ) peptide accumulation in the brain is cen-
tral to the pathogenesis of Alzheimer’s disease (AD). Aβ is
produced by the serial proteolysis of amyloid precursor pro-
tein (APP) by secretases [1]. APP processing to amyloido-
genic and non-amyloidogenic products is greatly affected
by the subcellular localization of APP, presumably because
of the specific subcellular localizations of secretases [2].
Non-amyloidogenic processing occurs mainly at the cell
surface, where α-secretase and γ-secretase cleave APP into
a soluble sAPPα fragment and non-toxic peptide p3. Amy-
loidogenic processing involves transit through endocytic
organelles, where APP encounters β- and γ-secretases that
cleave it into a soluble sAPPβ fragment and toxic Aβ pep-
tides [2]. APP-interacting proteins that alter APP trafficking
thus impact Aβ production.
Many members of the low-density lipoprotein receptor
(LDLR) family interact with APP and regulate its intracellu-
lar trafficking [3]. The LDLR family consists of a large class
of surface receptors usually involved in endocytosis and
lipid metabolism [4]. However, recent reports have indi-
cated that various members of this family play a role in
APP trafficking and processing and are important risk fac-
tors in AD (reviewed in [2]). LDLR-related protein 1
(LRP1), a multifunctional endocytic receptor, interacts with
APP and facilitates its internalization in endosomes and,
consequently, its cleavage into Aβ [5]. Genetic studies have
also linked LRP1 to AD [6]. SorLA (also called LR11 or
SorL1) is a unique member of the LDLR family that is
mainly localized in the trans-Golgi network (TGN) and
endosomes [7]. SorLA interacts with APP and acts as a re-
tention factor for APP in the Golgi, reducing its processing
by secretases [8-10]. Evidence of decreased levels of SorLA
in the brains of AD patients as well as epidemiological stud-
ies [8,11] point to an association between SorLA and AD.
Human LDLR-related protein 10 (LRP10, called LRP9 in
mice) is a member of a new subfamily of LDLR that
includes two other receptors, LRP3 and LRP12 [12]. This
unique subfamily of LDLR is characterized by extracellular
CUB domains and large cytoplasmic tails containing acidic
dileucine (DXXLL) motifs [13]. Little is known about
LRP10 apart from the fact that it is expressed in various tis-
sues (including the brain), may be involved in apolipopro-
tein internalization [14], and is localized in the TGN and
endosomes [13,15]. Two DXXLL motifs in the cytoplasmic
tail of LRP10 interact with the clathrin adaptor GGA and
AP proteins and are involved in LRP10 shuttling between
the TGN and endosomes [13,15]. This strongly suggests
that LRP10 plays a role in ligand trafficking between these
intracellular compartments.
In the present study, we tested the hypothesis that
LRP10 is a novel APP receptor involved in APP traffick-
ing and processing to Aβ and explored its potential in-
volvement in AD.Results
LDLR-related protein 10 (LRP10) is a novel APP-
interacting protein
We initially evaluated the ability of LRP10 to bind APP since
such binding would indicate that LRP10 plays a role as an
intracellular APP receptor. We first performed immunopre-
cipitation experiments on HEK293 cells transfected with
HA-tagged LRP10 and green fluorescent protein (GFP) or
GFP-tagged APP. LRP10-HA coprecipitated with GFP-APP
but not with GFP when we performed the immunoprecipita-
tion with anti-HA immunoglobulin (IgG) (Figure 1A). This
interaction was confirmed using untagged APP (Additional
file 1: Figure S1) and using a combination of lysates from
cells that expressed LRP10-HA and GFP-APP separately
(Additional file 2: Figure S2). These results indicated that
overexpressed APP and LRP10-HA interact within cell
lysates. We next looked at whether endogenous APP inter-
acts with LRP10 in HEK cells transfected only with HA-
tagged LRP10. LRP10-HA coimmunoprecipitated with APP
in the presence of anti-APP, confirming that LRP10 interacts
specifically with endogenous APP (Figure 1B).
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tacts in the extracellular (luminal) and/or cytoplasmic
regions of both proteins. To determine the importance of
the extracellular and intracellular domains of LRP10 for the
interaction with APP, we transfected HEK293 with APP695
together with FLAG-tagged LRP10 mutants that lacked ei-
ther the cytoplasmic domain (LRP10ΔCD) or the extracellular
or ectodomain (LRP10ΔED) (Figure 2A). Immunoprecipita-
tions were performed with either anti-APP or anti-FLAG
antibodies. A weak interaction was detected between APP695
and LRP10 ΔED while a stronger interaction was observed be-
tween APP695 and LRP10
ΔCD (Figure 2B), suggesting that
the ectodomain of LRP10 is the major determinant for the
interaction between LRP10 and APP. Lastly, we used pull-
down assays to verify the in vitro interactions between
LRP10 and the extracellular (luminal) region of APP (GST-
APP N-term) and the cytoplasmic region of APP (GST-APP
C-term) (Figure 2C). 35 S-labeled in vitro-translated LRP10
bound strongly to GST-APP-N-terminus and weakly to
GST-APP-C-terminus compared to GST alone (Figure 2D).
These results indicated that LRP10 interacts directly and pre-
dominantly with the ectodomain of APP in vitro.
LRP10 colocalizes with APP in the TGN
To determine whether LRP10 colocalizes with APP, we
compared the intracellular distributions of HA-tagged
LRP10 and GFP-tagged APP in HeLa cells by confocal mi-
croscopy. We mainly detected wild-type LRP10-HA in the
juxtanuclear region and surrounding vesicles that codistri-
bute with TGN46 and EEA1, which are markers of the
trans-Golgi network (TGN) and early endosomes, respect-
ively (Figure 3B, E). This was in agreement with our previ-
ous findings showing that LRP9, the mouse homolog of
LRP10, localizes in the TGN and in endosomes in the
Golgi area [13]. GFP-tagged APP was concentrated in the
Golgi region, where it partially colocalized with LRP10wt-
HA and TGN46 (Figure 3B, Merge) as well as surround-
ing EEA1-labeled vesicles (Figure 3E, Merge). The distri-
bution of GFP-APP in cells expressing LRP10wt-HA was
not mainly different from the distribution observed in
control cells (Figure 3A, D). The results of the IF and bio-
chemical interaction assays (immunoprecipitation and
pull-down) suggested that LRP10 interacts with APP in
the TGN cisternae and in the surrounding endosomes.
LRP10 affects the intracellular distribution of APP in HeLa
cells
To investigate the functional role of LRP10 on APP intra-
cellular transport, we examined the subcellular distribu-
tion of APP in HeLa cells expressing an LRP10-trafficking
mutant (LRP102DXXAA). We and others recently showed
that the substitution of leucines by alanines in two DXXLL
motifs of the cytoplasmic tail of LRP9 (mouse homolog of
LRP10) inhibits the interaction of LRP9 with clathrinadaptors AP-1/AP-2 and GGAs (Golgi-localized, γ-ear
containing ARF-binding proteins) and causes its mislocali-
zation to the endosomes and plasma membrane (PM)
[13,15]. In concordance with the fact that the cytoplasmic
tail of LRP10 has 83% homology with LRP9, the mutation
of the two DXXLL motifs conserved in the cytoplasmic
tail of LRP10 (LRP102DXXAA) induced its redistribution to
the cell surface and to peripheral punctate structures
(Figure 3C, F). As previously observed with LRP92DXXAA
[13], a confocal microscopic assessment of the distribution
of HA-tagged LRP102DXXAA with TGN46 and EEA1 con-
firmed that the DXXAA mutations shifted the distribution
of LRP10 from the TGN to the PM and peripheral early
endosomes (Figure 3F). Interestingly, the intracellular dis-
tribution of GFP-APP was modified in cells expressing the
LRP102DXXAA-trafficking mutant. In addition to its distri-
bution in the Golgi region (Figure 3C), GFP-APP coloca-
lized with LRP102DXXAA in peripheral EEA1-labeled
endosomes and at the PM (Figure 3F). Furthermore, co-
immunoprecipitation assays confirmed that HA-tagged
LRP102DXXAA interacted with APP (Additional file 1:
Figure S1). We concluded that the DXXLL motifs are
required for the proper trafficking of LRP10 but not
for the formation of the LRP10:APP complex. As
such, the LRP102DXXAA mutant was able to redistrib-
ute APP to peripheral early endosomes.
To better understand how the LRP102DXXAA mutant affects
the distribution/trafficking of APP, we first investigated the
precise intracellular trafficking pathways of LRP10wt and of
LRP102DXXAA in order to precisely define the intracellular traf-
ficking step impaired by the DXXLL motifs mutation. Since
LRP10wt is intracellular while the LRP102DXXAA mutant dis-
plays strong cell surface and endosome localization, it is pos-
sible that LRP10 constantly cycles between the TGN and the
endosomes by transiting through the plasma membrane and
that the mutation of both DXXLL motifs delays either its
internalization and/or its retrograde transport from the endo-
some to the Golgi. Alternatively, it is possible that LRP10wt
never reaches the plasma membrane and that the DXXLL
mutations promote the exit from the TGN and default trans-
port to the plasma membrane. To distinguish between these
two possibilities, we examined the presence of LRP10wt at the
cell surface of HeLa cells transfected with LRP10wt tagged with
an extracellular FLAG epitope. The cells were incubated with
a specific anti-FLAG monoclonal antibody at 4°C to label the
FLAG-LRP10wt at the cell surface. The cells were then incu-
bated at 37°C, and the uptake of cell-surface labeled FLAG-
LRP10wt was analyzed. At the initial time point, low level of
FLAG-LRP10wt was observed at the cell surface (Figure 4A).
After 5 or 10-min chase, cell-surface labeled FLAG-LRP10wt
was observed in EEA1-labeled endosomes (Figure 4C, E).
After a 60-min chase, it accumulated in the Golgi region,
where it partially colocalized with TGN46 (Figure 4G), while
after a 120 min chase, it clearly colocalized with TGN46
Figure 2 Interaction of the ectodomains of LRP10 and APP. (A) Schematic representation of the LRP10 FLAG-tagged deletion mutants used
to determine the binding domain of APP. The structural elements of LRP10 are depicted, including (from amino to carboxyl terminus) the CUB
domains, LDLRA repeat, and transmembrane (TM) domain. CD, Cytoplasmic domain; ED, Ectodomain. (B) The interaction between LRP10 and APP
does not depend on the cytoplasmic domain of LRP10. Lysates of HEK cells transfected with APP695 and pcDNA3-FLAG, FLAG-tagged LRP10
ΔCD,
or FLAG-tagged LRP10ΔED were immunoprecipitated with anti-APP or anti-FLAG and were immunoblotted with anti-APP or anti-FLAG antibody.
(C) Schematic representation of the GST-APP deletion mutants used to determine the binding domain of LRP10. The structural elements of APP
are depicted, including the cysteine, acidic, carbohydrate, amyloid beta, and cytoplasmic domains. (D) In vitro interaction of LRP10 with the
ectodomain of APP. The APP deletion mutants shown in (C) and the GST protein (10 μg each) were immobilized on glutathione beads and were
incubated with in vitro translated 35 S-labeled LRP10. Bound proteins were separated by SDS-PAGE and were detected by autoradiography. GST
proteins were detected by coomassie staining. Input equaled 2.5% of the total in vitro-translated product.
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extracellular FLAG epitope were detected on the cell surface
(Figure 4B). The uptake analysis of cell surface labeled FLAG-
LRP102DXXAA showed that it was still mainly distributed at the
plasma membrane after a 5-min chase (Figure 4D) but was
clearly present in endosomes after a 10-min chase (Figure 4F),Figure 3 LRP10 colocalizes with APP and modulates its intracellular d
vector pcDNA3 (A, D), wild-type LRP10-HA, (LRP10wt-HA; B, E), or HA-tagged
GGAs and AP1/2) in the cytoplasmic tail were mutated (LRP102DXXAA-HA, C
(green), anti-HA (red), and anti-TGN46 or EEA1 (blue) antibodies. The labele
control pcDNA3 cells, APP-GFP was detected mainly in the juxtanuclear reg
(A, inset, arrowheads) and EEA1 (D, inset, arrowheads). (B, E) LRP10wt-HA w
partially overlapped with TGN46 (B) and EEA1 (E). In these cells, GFP-tagged
overlapped with LRP10wt-HA (B). The merged images show a partial overla
TGN46 (B, inset, arrowheads) and surrounding endosomes labeled by EEA1
to the plasma membrane (arrows) and peripheral early endosomes (F, inse
(F, inset, arrow), Golgi (C, inset) and in peripheral endosomes labeled by EE
inset). Scale bar, 10 μm.suggesting that its internalization was delayed compared to
FLAG-LRP10wt. However, int-LRP102DXXAA was still pre-
sent in this compartment after a 60 and 120-min chase
(Figure 4H, J). This result suggested that the normal trafficking
itinerary of LRP10 involves a transit to the plasma membrane,
internalization, and retrograde transport from the endosomeistribution. HeLa cells were transfected with GFP-APP and control
-LRP10 in which two DXXLL motifs (that bind the clathrin adaptors
, F). Cells were fixed, permeabilized, and immunostained with anti-GFP
d cells were examined by confocal fluorescence microscopy. (A, D) In
ion and surrounding vesicles where it partially overlapped with TGN46
as detected in the juxtanuclear region and surrounding vesicles and
APP was detected mainly in the Golgi region, where it partially
p between LRP10wt-HA and GFP-APP in the Golgi cisternae labeled by
(E, inset, arrowheads). (C, F) HA-tagged LRP102DXXAA was redistributed
t). In these cells, GFP-APP was also detected on the plasma membrane
A1 (F, inset), where it colocalized with LRP102DXXAA-HA (F, arrowheads,
Figure 4 (See legend on next page.)
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Figure 4 Comparison of the intracellular trafficking pathways of LRP10wt and LRP102DXXAA. The internalization of LRP10 was evaluated in
HeLa cells transfected with LRP10wt or LRP102DXXAA tagged with an extracellular FLAG epitope. The cells were pre-incubated on ice to arrest
endocytosis, and LRP10 molecules exposed on the cell surface were immunolabeled with antiserum directed against FLAG at 4°C. The cells were
then washed and incubated at 37°C to allow internalization. Endocytosis and TGN targeting of cell surface-labeled LRP10 were evaluated after 0,
5, 10, 60, and 120-min chases at 37°C. The cells were then fixed, permeabilized, and immunostained with anti-TGN46 (green) or anti-EEA1 (blue)
antibodies. The labeled cells were examined by confocal fluorescence microscopy. In cells expressing FLAG-LRP10wt, low level of FLAG-LRP10wt
was observed at the cell surface at time 0 (A, inset, arrows). Internalized LRP10wt (int-LRP10wt) was observed in vesicles near the plasma
membrane following a 5-min (C) and a 10-min (E) chase where it colocalized with EEA1 (C, E, insets, arrowheads). After a 60-min chase,
int-LRP10wt localized in the Golgi region and partially colocalized with the TGN marker TGN46 (G, inset, arrowheads). This colocalization was
higher after a 120-min chase (I, inset, arrowhead). In cells expressing FLAG-LRP102DXXAA, large amounts of LRP102DXXAA were detected on the cell
surface at time 0 (B, arrows). After a 5-min chase, int-LRP102DXXAA was still distributed at the plasma membrane (D, arrow) or partially colocalized
with EEA1 in vesicles near the PM (D, inset, arrowheads). After a 10-min chase, int-LRP102DXXAA was observed in EEA1-labeled vesicles (F, inset,
arrowheads). However, after a 60-min chase (H), and even a 120-min chase (J), int-LRP102DXXAA was still mainly observed in early endosomes
(H, J, insets, arrowheads). Scale bar, 10 μm.
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reach the PM and be internalized slowly into early endosomes.
However, its exit from this compartment would be compro-
mised. These results suggested that LRP10 moves through the
secretory pathway to the cell surface. After rapid
internalization in early endosomes, LRP10 is recycled back to
the Golgi, a step that requires the DXXLL motifs in the cyto-
plasmic tail of LRP10 .
To determine whether LRP10 participates in the
internalization and retrograde transport of cell surface APP
to the TGN, we next analyzed the uptake of cell surface-
labeled APP in cells overexpressing APP695 and HA-tagged
LRP10wt or LRP102DXXAA (Figure 5A-F). No altered
internalization behavior was seen for APP coexpressed with
LRP10wt since cell surface labeled-APP colocalized with
TGN46 after a 60-min incubation (Figure 5B, arrowheads),
as observed in control cells (Figure 5A, arrowheads), indicat-
ing that APP reached the Golgi. However, in cells expressing
LRP102DXXAA, APP colocalized with EEA1 (Figure 5F, arrow-
heads) and did not redistribute to the TGN, even after
60 min (Figure 5C, arrows), indicating that APP was retained
in the endosomes. We noticed that the half-life of APP is
extended in this assay since cell-surface labeled APP could
still be detected in the cells after 60 min internalization. This
could be explained by the high amount of internalized APP
due to overexpression or the presence of anti-APP antibodies
internalized with APP that could affect or delay the proces-
sing of APP. In summary, these results suggested that LRP10
activity does not influence APP uptake from the cell surface
while LRP102DXXAA inhibits the retrograde transport of APP
from the endosome to the TGN.
LRP10 affects the trafficking of endogenous APP in
SH-SY5Y cells
To confirm the role of LRP10 in the redistribution of
APP in a system that more closely mimics physiological
conditions, we investigated the effect of LRP10 overex-
pression on the distribution of APP in SH-SY5Y cells, ahuman neuroblastoma cell line that expresses endogen-
ous APP but little endogenous LRP10 protein (data not
shown). We generated SH-SY5Y cells that stably
expressed pcDNA3 (control) as well as high levels of
HA-tagged LRP10wt or HA-tagged LRP102DXXAA. In the
control cells, endogenous APP was localized in the TGN
and in surrounding EEA1-labeled vesicles (Figure 6A, D).
In cells expressing LRP10wt, APP labeling was stronger in
the TGN compartment, where it colocalized with LRP10wt
(Figure 6B, Merge). As with HeLa cells, the expression of
LRP102DXXAA in SH-SY5Y cells led to a redistribution of
APP from the TGN to peripheral early endosomes, where
it colocalized with HA-tagged LRP102DXXAA (Figure 6F,
Merge). In these cells, plasma membrane labeling of
LRP102DXXAA and APP was less prominent. These obser-
vations suggested that LRP10 affects the intracellular dis-
tribution of APP in human neuronal SH-SY5Ycells.
We next examined the effect of LRP10 on the redistri-
bution and surface expression of APP using a cell surface
biotinylation assay. SH-SY5Y cells stably expressing
pcDNA3, LRP10wt, or LRP102DXXAA were incubated with
a membrane-impermeable biotin reagent at 4°C. A frac-
tion of the total cell lysates and the biotinylated proteins
were resolved by SDS-PAGE analysis, and LRP10 and
APP expression was determined by Western blotting
(Figure 6G). As previously reported, APP695, APP751, and
APP770, three variants of endogenous APP, were detected
in these cells [16,17]. As predicted by the immunofluores-
cence observations, overexpression of LRP102DXXAA
resulted in the accumulation of APP together with
LRP102DXXAA on the cell surface (Figure 6G). In contrast,
while a small amount of LRP10wt was detected on the
plasma membrane of SH-SY5Y cells overexpressing
LRP10wt, the amount of APP on the cell surface was lower
than that of control (pcDNA3) cells (Figure 6G). The cell
lysates revealed that the levels of the APP variants were
similar in the different SH-SY5Y clones (Figure 6G). Inter-
estingly, overexpression of LRP10wt resulted in the
Figure 5 LRP102DXXAA inhibits the retrograde transport of APP from the endosome to the TGN. Internalization of APP was evaluated in
HeLa cells transfected with APP695 and pcDNA3 (A, D), HA-tagged LRP10
wt (B, E), or LRP102DXXAA (C, F). The cells were pre-incubated on ice to
arrest endocytosis, and APP molecules exposed on the cell surface were immunolabeled with antiserum directed against APP (α-22 C11) at 4°C.
Endocytosis and TGN targeting of APP were evaluated after 60-min chase periods at 37°C. Cells were then fixed, permeabilized, and
immunostained with anti-HA (red) and anti-TGN46 or anti-EEA1 (blue) antibodies. The labeled cells were examined by confocal fluorescence
microscopy. In cells expressing pcDNA3 and LRP10wt-HA, internalized APP (int-APP, green) was localized in the Golgi region and partially
colocalized with the TGN marker TGN46 (A, B, arrowheads). However, in cells expressing LRP102DXXAA-HA, internalized APP (int-APP) was
distributed mainly in vesicles labeled with the endosomal marker EEA1 and LRP102DXXAA-HA (F, arrowheads). Arrowheads indicate structures in
which APP colocalized with TGN46 or EEA1 while arrows indicate structures in which APP and TGN46 or EEA1 did not colocalize. Scale bar,
10 μm.
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compared to the control and LRP102DXXAA cells
(Figure 6G, asterisks). This higher molecular weight form
of APP corresponds to the mature (glycosylated) form of
APP751/770 [17,18]. The accumulation of the mature APP
species in the presence of LRP10wt was confirmed by
studying the time course of APP maturation using [35 S]
methionine pulse-chase experiments (Figure 6H). The
emergence of mature forms of APP followed similar kinet-
ics in cells without LRP10 and with LRP10wt or
LRP102DXXAA (30-min chase), but the half-life of the ma-
ture APP protein was longer in the presence of LRP10wt
(Figure 6H), as shown by the ratio of signal intensities for
mature versus immature APP species (120-min chase;
p< 0.005) (Figure 6H). In summary, overexpression of
LRP10wt resulted in higher amounts of mature APP,
with an accumulation of APP in the TGN and loweramounts on the cell surface, suggesting that APP is
retained in the TGN. In contrast, overexpression of
LRP102DXXAA resulted in higher amounts of APP on
the cell surface and an accumulation in endosomes,
suggesting that APP recycling to the TGN was
impaired.
LRP10 alters the processing of APP in SH-SY5Y cells
To establish a causal role for LRP10 in APP trafficking, we
examined the effect of LRP10 overexpression on the proces-
sing of APP in SH-SY5Y cells stably expressing pcDNA3,
HA-tagged LRP10wt, or HA-tagged LRP102DXXAA. We inves-
tigated whether LRP10 altered the generation of APP proces-
sing products using Western blotting to detect total soluble
APP fragment (sAPPα+sAPPβ) as well as intracellular β-
carboxy-terminal fragment (β-CTF) levels (Figure 7A). In
parallel, AlphaLISA assays were performed to specifically
Figure 6 (See legend on next page.)
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Figure 6 LRP10 affect the trafficking of APP in neuronal SH-SY5Y cells. (A-F) LRP10 colocalized and altered the distribution of endogenous
APP. SH-SY5Y cells were stably transfected with empty pcDNA3 vector (A, D) or high levels of HA-tagged-LRP10wt (B, E) or -LRP102DXXAA (C, F).
Cells were fixed, permeabilized, and immunostained with anti-APP (green), anti-HA (red), and anti-TGN46 or anti-EEA1 (blue) antibodies. The
labeled cells were examined by confocal fluorescence microscopy. (A, D) In control cells (pcDNA3), endogenous APP was detected mainly in the
Golgi region where it partially overlapped with TGN46 (A, inset arrowheads) and surrounding vesicles where it partially overlapped with EEA1 (D,
inset, arrowheads). (B, E) LRP10wt-HA was detected in the TGN (B, inset) and surrounding EEA1-labeled endosomes (E, inset). Endogenous APP
was mainly detected in the Golgi region, where it partially overlapped with LRP10wt-HA (B, inset). The merged image shows a clear overlap
between LRP10wt-HA and endogenous APP in the TGN (B, arrowheads, insets). (C, F) LRP102DXXAA-HA was redistributed mainly to peripheral
EEA1-labeled early endosomes (F, inset). Endogenous APP was also detected in peripheral EEA1-labeled endosomes (F, inset), where it colocalized
with HA-tagged LRP102DXXAA (F, arrowheads, inset). Scale bar, 10 μm. (G) The level of cell surface APP was altered by the expression of LRP10. SH-
SY5Y cells stably expressing pcDNA3 vector or high levels of HA-tagged-LRP10wt or -LRP102DXXAA were surface-biotinylated with sulfo-NHS-SS
-biotin. Biotinylated proteins were precipitated with neutravidin, and samples (Surface proteins) were analyzed by immunoblotting with antisera
directed against HA or APP. The total cell lysate (Total proteins) was also analyzed to assess APP and LRP10 expression levels. The three APP
variants (APP695, APP751, and APP770) were detected by the anti-APP antibodies. The asterisk indicates an accumulation of mature APP
(glycosylated APP751/770) in the presence of LRP10
wt. Actin was used as a loading control. (H) The maturation of APP was altered in SH-SY5Y cells
expressing LRP10wt. SH-SY5Y control cells or cells stably expressing LRP10wt or LRP102DXXAA were pulse-labeled with [35 S]methionine for 5 min
and chased at 37°C for the indicated time. Radiolabeled APP was immunoprecipitated from the cell extracts and was analyzed by SDS-PAGE and
autoradiography. The three APP variants (APP695, APP751, and APP770) are indicated by arrowheads. Accumulations of mature APP (*, indicates
mature APP751/770; +, indicates mature APP695) were observed in cells expressing LRP10
wt. Graph of the ratio of mature (m) APP versus immature
(im) APP in the indicated SH-SY5Y stable clones as determined by densitometric scanning of pulse-chase experiments exemplified in the
autoradiogram above. The results indicated that there is a delayed turnover of the mature, fully glycosylated APP variants when they are co-
expressed with LRP10wt. Results are expressed as means ± SD (n = 3). *, p< 0.05; **, p< 0.005 (compared to control cells).
Brodeur et al. Molecular Neurodegeneration 2012, 7:31 Page 10 of 19
http://www.molecularneurodegeneration.com/content/7/1/31detect and quantify the secretion of sAPPα, sAPPβ, and the
Aβ40 peptide into the cell culture media (Figure 7B). The ex-
pression of LRP10wt in SH-SY5Y cells resulted in lower total
sAPP and β-CTF levels as assessed by Western blotting
(Figure 7A). This was confirmed and quantified by Alpha-
LISA (Figure 7B). Compared to control cells, LRP10wt ex-
pression caused a 23% decrease (p< 0.001) in sAPPα, 42%
(p< 0.001) in sAPPβ, and 55% (p< 0.001) in Aβ40 levels
(Figure 7B). In contrast, the expression of LRP102DXXAA
increased sAPP and β-CTF levels as assessed by Western
blotting (Figure 7A). The AlphaLISA assays indicated that
there was no significant effect on the secretion of sAPPα
(p=0.06) but that sAPPβ levels increased by 66% (p< 0.005)
compared to control cells (Figure 7B). Unexpectedly, we
observed a 26% decrease in Aβ40 levels (p< 0.005)
(Figure 7B), suggesting lower γ-secretase cleavage of β-CTF.
This was confirmed by the decrease in AICD fragments that
arise as a co-product of β-CTF cleavage by γ-secretase
(Additional file 3: Figure S3). To determine whether this ef-
fect was due to the high levels of LRP102DXXAA expression,
we examined the APP processing products in SH-SY5Y cells
stably expressing low levels of LRP102DXXAA. As observed in
SH-SY5Y stably expressing high levels of LRP102DXXAA,
Western blots revealed that there was an increase in sAPP
and β-CTF levels (Figure 7A) while the AlphaLISA assays
indicated that there was no significant effect on the secretion
of sAPPα (p> 0.05) but an increase in sAPPβ (Figure 7B).
However, unlike the SH-SY5Y clone expressing high levels of
LRP102DXXAA, Aβ40 levels increased by 40% (p< 0.001)
compared to control cells, in SH-SY5Y cells stably expressing
low levels of LRP102DXXAA (Figure 7B). We attempted to
measure Aβ42 in the different SH-SY5Y clones, but the levels
of endogenously produced Aβ42 were below reliabledetection limits. In summary, the overexpression of LRP10wt
resulted in decreased non-amyloidogenic and amyloidogenic
processing. The same results were observed in SH-SY5Ycells
stably expressing low levels of LRP10wt (data not shown). In
contrast, low levels of LRP102DXXAA expression increased
the amyloidogenic processing of APP. However, while high
levels of LRP102DXXAA expression increased amyloidogenic
processing, as indicated by the increases in sAPPβ and β-
CTF, the Aβ40 levels was unexpectedly decreased. The ex-
pression of LRP102DXXAA thus increased the amyloidogenic
processing of APP, which was expected since this LRP10 mu-
tant increased the presence of APP in endosomes, the princi-
pal location of β-secretase. However, high LRP102DXXAA
levels seemed to affect the γ-secretase cleavage of β-CTF and
in turn to reduce Aβ40 production.
Given that the overexpression of LRP10 decreased APP
processing, we theorized that a decrease in LRP10 expres-
sion would result in the opposite effect. To test this possi-
bility, we performed siRNA experiments in which LRP10
siRNA was transiently transfected into SH-SY5Y cells stably
expressing low levels of HA-tagged LRP10. The siRNA
treatment resulted in significantly lower LRP10 protein
levels in these cells than in the control cells (Additional
file 4: Figure S4). We used Western blots and Alpha-
LISA assays to determine the levels of β-CTF and
Aβ40, respectively (Additional file 4: Figure S4). β-
CTF levels were higher in the LRP10 knockdown cells
than in the control cells (Supplemental Figure 4A).
Similarly, Aβ40 levels were 17% higher in LRP10-
depleted cells than in the control cells (p = 0.001,
Supplemental Figure 4B). These results indicated that
reducing LRP10 levels causes a significant increase in
amyloidogenic processing of APP. The low transfection
Figure 7 LRP10 overexpression alters APP processing in SH-
SY5Y cells. APP cleavage products in SH-SY5Y stable clones
expressing pcDNA3 vector alone (Ctl) or HA-tagged LRP10wt or
LRP10 trafficking mutant LRP102DXXAA. (A) Representative Western
blot of total sAPP secreted in the media and of β-CTF and total APP
in the cell lysates of the indicated SH-SY5Y stable clones. Actin was
used as loading control. (B) AlphaLISA quantitative analysis of sAPPα,
sAPPβ, and Aβ40 in the media of the SH-SY5Y stable clones
expressing pcDNA3 vector alone (Ctl), high level of HA-tagged
LRP10wt (LRP10wt) or low and high levels of LRP10 trafficking mutant
(LRP102DXXAA). Results are expressed as means ± SD (n= 3). *,
p< 0.01; **, p< 0.005; ***, p< 0.001 (compared with control cells).
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other APP receptors in these cells could explain the
weak effect of the LRP10 knockdown on the production
of Aβ40. In summary, aberrant LRP10 trafficking by
mutations in the DXXLL motif or the loss of LRP10expression led to altered APP processing and increased
Aβ40 production.LRP10 levels are reduced in Alzheimer’s disease brains
Based on the results obtained with the SH-SY5Y and HeLa
cells, LRP10 is a functional APP receptor that modulates
APP trafficking and reduces its processing into Aβ. This
finding raised the intriguing possibility that the increased
Aβ production observed in patients with AD may involve
the loss of LRP10 expression in the brain. This hypothesis
was tested using post-mortem brain tissues from AD
patients (Figure 8). Expression profiling of LRP10 in AD
was performed by comparing LRP10 protein and mRNA
levels in human frontal cortex and hippocampal tissue
samples from ten autopsy-confirmed cases of AD and ten
age-matched controls (Figure 8). The mean age at the
time of death was 71.7± 7.2 years (range, 57–82 years) for
the control subjects and 76.4± 3.1 years (range, 70–
82 years) for the AD subjects. Patients suffering from AD
expressed less LRP10 protein than the healthy controls as
assessed by Western blotting (Figure 8A). Given that
neuronal loss is a characteristic of AD brains, we normal-
ized our Western blot findings to relevant markers to ac-
count for neuron-specific cell loss. When normalized to
neuron-specific Class III β-tubulin (Tuj1), we found that
LRP10 expression in the frontal cortex and hippocampus
of AD brains was 50% and 47% lower (p< 0.001), respect-
ively, than in control brains (Figure 8B). Interestingly, the
decrease in LRP10 levels in AD brains from the female
subjects was significantly higher than in those from the
male subjects. LRP10 levels in the frontal cortex and
hippocampus tissues of the male AD subjects were 31%
and 36% lower than in the control subjects, but 67% and
60% lower in the female AD subjects (Figure 8B). To de-
termine whether the decrease in LRP10 protein levels was
due to a change in gene expression, total quantitative RT-
PCR assays were performed on frontal cortex tissues from
five AD and five control brains (Figure 8C). There was no
significant difference between LRP10 mRNA levels in the
AD samples and the control samples (normalized LRP10
expression: 1.07± 0.44 in AD brains vs. 1.13± 0.88 in con-
trol brains, p = 0.4). In summary, our results indicated that
neuronal LRP10 protein levels are lower in the post-
mortem brain tissues of AD patients.Discussion
LRP10 is a distinct member of the LDLR family that transits
between the TGN, PM, and endosomes. However, the
physiological role of LRP10 is unknown. The similarities be-
tween LRP10 and SorLA trafficking led us to hypothesize
that LRP10 plays a role in APP metabolism. Our study
showed that LRP10 is a novel APP sorting receptor that
regulates APP trafficking and processing and provided
Figure 8 LRP10 levels in healthy and AD brains. Analysis of LRP10 protein and mRNA levels in healthy and AD brains. (A) LRP10 protein
expression in the frontal cortex and hippocampus of healthy (Control) and Alzheimer’s disease (AD) patients was compared by Western blotting.
Representative data showing lysates subjected to SDS-PAGE and immunoblotted with antisera directed against LRP10 and neuron-specific Class III
β-tubulin (TUJ1). (B) Densitometric analysis of Western blots, such as those shown in (A), normalized to the signal of TUJ1. Results are expressed
as means ± SD (n≥ 3). *, p< 0.01; **, p< 0.005; ***, p< 0.001 (compared with healthy patients). (C) LRP10 mRNA levels in the frontal cortex of
healthy (CTL) and AD patients were compared by qRT-PCR. Total mRNA was reverse transcribed, and the levels of LRP10 cDNA were analyzed by
qPCR with SYBR Green and were expressed relative to the endogenous control (RPL13) using the comparative CT method. Results are expressed
as means ± SD (n = 5 samples, in duplicate). The difference between CTL and AD was not significant (p = 0.4).
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of AD.
Our results revealed that there is a direct interaction be-
tween LRP10 and APP. Immunoprecipitation and in vitro
pull-down assays indicated that the ectodomain of LRP10 is
mainly involved in this interaction, much like SorLA and
APoER2, two other APP receptors that interact with APP via
their luminal domains [19,20]. Further studies will be needed
to map the precise APP binding regions in LRP10. A con-
focal microscopy analysis indicated that exogenous APP in
HeLa cells and endogenous APP in human neuronal SH-
SY5Y cells mainly colocalizes with LRP10 in the TGN and,to a lesser extent, in early endosomes, suggesting that LRP10
and APP interact in these subcellular compartments.
Various LDLR members have been shown to be involved
in the regulation of APP trafficking [2]. Our findings un-
cover LRP10 as a new LDLR member implicated in APP
sorting. This is supported by the APP phenotypes resulting
from the overexpression of wild-type LRP10 as well as the
LRP10 trafficking mutant. The overexpression of LRP10wt
in neuronal SH-SY5Y cells resulted in an accumulation of
APP in the TGN concomitant with a decrease at the cell
surface as well as higher amounts of mature APP with a
longer half-life. This suggested that the time of residence of
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APP molecules en route through the TGN to the cell sur-
face or by the retrograde transport of internalized APP
from the endosomes to the TGN. The second possibility is
in line with a proposed role for LRP10 in endosome-to-
Golgi trafficking [13,21]. However, there were no clear dif-
ferences in the appearance of internalized APP in the TGN
of HeLa cells transfected with APP in the absence or pres-
ence of LRP10wt, suggesting that LRP10 may control the
exit of APP from the TGN. A retention of APP in the Golgi
should cause an accumulation of mature APP molecules in
the cell. This possibility was supported by the fact that SH-
SY5Y cells stably expressing LRP10wt displayed higher levels
of mature APP molecules than control cells or cells expres-
sing the LRP102DXXAA trafficking mutant. This finding im-
plies that the exit of APP from the ER to the Golgi was
normal but that the ability to transit to more distal com-
partments was blocked by LRP10wt proteins, thus increas-
ing the amount of fully glycosylated APP molecules in the
cell. This possibility was further supported by the fact that
LRP10wt inhibits APP processing and, consequently,
reduces the turnover rate of mature APP. Further studies
are needed to clearly identify the trafficking steps regulated
by LRP10 as well as the molecular mechanisms involved.
The ability of LRP10 to regulate APP routing was con-
firmed by targeting LRP10 to the endosomes, which caused
an accumulation of APP in the same compartment. We
showed that the expression of mutated LRP102DXXAA,
which could not bind GGA and AP1/AP2 proteins, impairs
APP recycling to the TGN, since we observed that this
LRP10 mutant is unable to retrogradely transport it out of
the endosomes. Previous studies by the group of Kornfeld
[15] using a chimera containing the ectodomain of LRP4
and the cytoplasmic tail of LRP9 (mouse LRP10) indicated
that the mutation of the DXXLL motifs of LRP9 causes a
decrease in its internalization rate in CHO cells [15], which
could explain the accumulation of LRP102DXXAA and APP
at the cell surface. Our IF uptake assays, which indicated
that there is a delay in the internalization of FLAG-
LRP102DXXAA compared to FLAG-LRP10wt provided
support for this possibility. As such, the enhanced ex-
pression of LRP102DXXAA on the cell surface would
not be caused by mistargeting of LRP10 to the plasma
membrane due to a disrupted AP1/2, GGA-binding
motif, but to slower internalization from the cell sur-
face. These findings suggested that APP is a likely
physiological target for LRP10-mediated protein sort-
ing in neurons.
Mounting evidence has shown that alterations in the
intracellular distribution of APP have a direct impact on
amyloidogenic and non-amyloidogenic processing [2].
APP targeting and time of residence in endosomes are
known to modulate β-secretase cleavage and Aβ levels,
while the transport of APP to the cell surface modulatesits cleavage by α-secretase [2,22]. The relevance of LRP10-
mediated Golgi retention of APP was confirmed by the
distinct effect that LRP10wt and LRP102DXXAA had on Aβ
production. The retention processes induced by LRP10wt
would allow for more APP to be kept in circulation for
longer times and to be kept away from endosomes or the
PM, where it would be processed. The lower levels of
amyloidogenic and non-amyloidogenic processing pro-
ducts detected in these cells corroborated this hypothesis.
The relevance of LRP10-mediated Golgi retention/retrieval
of APP was confirmed by the significant increase in
amyloidogenic processing induced by siRNA depletion of
LRP10. We also showed that the targeting and retention
of APP in endosomes when LRP102DXXAA is expressed
increases APP cleavage by the amyloidogenic pathway
but does not significantly affect non-amyloidogenic pro-
cessing. As such, APP cleavage by endosomal β-secretase
increased and resulted in the production of more Aβ.
LRP10 also affected β-CTF cleavage, with high expression
levels of LRP102DXXAA appearing to increase sAPPβ and
β-CTF levels but decrease Aβ and AICD levels, suggest-
ing lower γ-secretase cleavage of β-CTF. Interestingly,
previous studies have indicated that members of the
LDLR family such as LRP and SorLA interact with and
are cleaved by γ-secretase [23,24] and also compete with
APP for this enzyme [23]. LRP10 may thus be either a
substrate for γ-secretase and compete with APP for this
enzyme or might affect γ-secretase distribution and activ-
ity. We intend to investigate these possibilities in future
studies.
In summary, we propose a model whereby LRP10wt is a
sorting receptor that cycles between the TGN and the
endosomes by transiting through the plasma membrane
(Figure 9). LRP10wt would traffic from the TGN to the
plasma membrane via the constitutive secretory pathway.
LRP10wt would next internalize from the cell surface into
early endosomes where it would recycle back to the TGN
(Figure 9). However, we cannot exclude the possibility that
LRP10wt could also traffic from the TGN directly to endo-
somes and next be retrogradely transported to the TGN or
anterogradely transported to the plasma membrane.
Through its direct interaction with APP, LRP10wt would
prolong the time of residence of APP in the TGN either by
TGN retrieval or retention and such, reduce the presence
of APP at the cell surface and in endosomes as well as its
cleavage by the secretases in these compartments (Figure 9).
LRP102DXXAA, which cannot be retrogradely transported
from the endosomes to the Golgi, would accumulate with
APP in the endosomes (Figure 9). This mislocalization
would promote access to the amyloidogenic secretases in
endosomes, leading to a higher production of Aβ (Figure 9).
Therefore, changes in LRP10 distribution or expression
would modify the balance between amyloidogenic and non-
amyloidogenic processing.
Figure 9 Model for the role of LRP10 in APP trafficking. LRP10 is
transported from the Golgi to the plasma membrane in the
secretory pathway independent of the DXXLL motifs. LRP10wt is
rapidly internalized from the cell surface into early endosomes
where it is efficiently recycled back to the Golgi. LRP10 may also
traffic directly from the TGN to the endosomes. LRP102DXXAA, which
is unable to associate with GGAs and AP1/2, is slowly internalized
from the plasma membrane and accumulates in the early
endosomes, since it is incapable of recycling to the TGN. APP is
constitutively transported to the plasma membrane and internalized
in endosomes. Interaction of APP with LRP10wt prolonged its
presence in the TGN. LRP10 could trap APP in the TGN (1), reducing
the amount of APP transported to the cell surface for non-
amyloidogenic processing by α- and γ-secretases. In addition, LRP10
may shuttle APP from early endosome back to the TGN (2), reducing
its amyloidogenic processing by β- and γ-secretases. LRP102DXXAA
traps APP in endosomes (3), resulting in enhanced accessibility to
amyloidogenic secretases and thus processing into Aβ.
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role in amyloidogenic processing. Most of these LDLR are
localized at the PM and modulate APP endocytosis rates
and cleavage in endosomes [2,3]. To date, only SorLA has
been reported to regulate APP trafficking to the TGN.
SorLA, like LRP10, retains APP in the Golgi compart-
ment, increases the half-life of mature APP, and reduces
APP processing by β-secretase in the early endosome, thus
decreasing the production of Aβ [8,9]. LRP10 and SorLA
are distinct LDLR members. Their only common domain
is a ligand-binding repeat. However, they are homologous
in terms of their trafficking pathways and regulation of
APP trafficking and processing and are both present at
lower levels in AD. These observations suggest that the
regulation of every trafficking steps targeting APP to dis-
tinct subcellular compartments is shared by many sorting
receptors, which highlights the importance of proper APP
distribution.
The relevance of LRP10 for APP processing and its po-
tential contribution to the pathogenesis of AD is supportedby the observation that LRP10 is expressed at much lower
levels in the brains of AD patients, which would result in
higher Aβ levels in these patients. Interestingly, we
observed that LRP10 levels in the brains of female AD
patients are significantly lower than those of male AD
patients, suggesting that LRP10 may affect AD through a
female-specific mechanism. This observation requires fur-
ther confirmation since it was based on a limited sample
size (5 men and 5 women). Nevertheless, similar observa-
tions of AD sexual dimorphisms have been reported for
two other members of the LDLR family that are known to
be APP receptors and that share trafficking homology with
LRP10. Indeed, there is a stronger genetic linkage to SorLA
and SorCS1 (a homolog of SorLA) in women than in men
in AD populations [25,26]. Higher Aβ levels have also been
observed in the brains of female Sorcs1 hypomorphic mice
but not in the brains of male mice [27]. The higher preva-
lence of alterations to these APP receptors (including
LRP10) in women is an important outcome since women
account for 72% of all AD cases. However, the reasons for
this are poorly understood.
In summary, our results suggested that altered LRP10
activity may be a potential risk factor for AD. The reason
for reduced LRP10 expression in AD individuals remains
to be determined. LRP10 mRNA levels do not change in
AD. As such, the lower LRP10 protein levels seen in AD
are not due to LRP10 gene transcription problems but ra-
ther to changes in protein translation or trafficking and
stability of the receptor. The identification of the molecu-
lar events responsible for the proper localization and ex-
pression of this receptor is thus crucial. Interestingly,
decreases in Calnuc and GGA proteins, which modulate
LRP10 trafficking and levels [13,21], have been associated
with AD [28-30]. Efforts should now be focused on identi-
fying and studying human genetic variants of LRP10 to
determine whether they are associated with AD in a sex-
dependent fashion. The identification of functional causa-
tive variants influencing LRP10 expression and/or levels
may help clarify their role in the pathogenesis of AD and
may lead to possible future therapeutic strategies.
Conclusions
Our experiments identified LRP10 as a novel APP sort-
ing receptor that protects against amyloidogenic proces-
sing of APP and the accumulation of the Aβ peptide.
Consequently, the reduced LRP10 receptor expression
observed in the human brain may increase Aβ produc-




Anti-HA mouse monoclonal antibodies (mAbs) and rabbit
polyclonal antibodies (pAbs) were purchased from
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rabbit pAbs were from Clontech (Mountain View, CA,
USA) and Molecular Probes (Eugene, OR, USA), respect-
ively. Mouse anti-APPA4 clone 22 C11 mAbs (a.a. 66–81,
N-term.) and rabbit anti-APP pAbs (C-term.) were from
Millipore (Billerica, MA, USA) and Invitrogen (Carlsbad,
CA, USA), respectively. Rabbit anti-LRP10 pAbs were
from Abnova (Walnut, CA, USA). Mouse anti-Flag M2
mAbs and rabbit anti-Flag pAbs were purchased from
Sigma (Oakville, ON, Canada). Mouse anti-actin AC-40
mAbs were from Sigma (Oakville, ON, Canada). Rabbit
anti-EEA1 pAbs were from Thermo Scientific (Ottawa,
ON, Canada) and were used for IB while goat anti-EEA1
was from Santa Cruz Biotechnology (Santa Cruz, CA,
USA) and was used for IF. Sheep anti-TGN46 pAbs were
from Novus Biologicals (Littleton, CO, USA).
DNA constructs
Mammalian expression vector pCMV6-Entry encoding
the human LRP10 was purchased from OriGene (Rock-
ville, MD, USA). LRP10 was subcloned in the pcDNA3.1
vector, and PCR-based mutagenesis was used to insert
an HA-tag at the C-terminus of LRP10 or a FLAG-tag
after the signal peptide of LRP10. The LRP10 double
DXXLL mutant construct was generated as described
previously [13,15]. LRP10 fragments containing the N-
terminus (residues 1–470) or C-terminus (residues 434–
712) were amplified by PCR and subcloned in pcDNA3.
Mammalian expression vectors GFP-APP695 and GST-
APP695 C-term (residues 647–695) were kindly provided
by Dr. Ritva Tikkanen (University Clinic of Frankfurt,
Germany) [31]. The APP695 fragment containing the N-
terminus (residues 20–612) was amplified by PCR and
subcloned in pET41a (Novagen). All constructs were
sequenced before being used.
Cell cultures and transfections
HeLa and SH-SY5Y cells were purchased from ATCC
(American Type Culture Collection, Manassas, VA, USA).
HEK cells were kindly provided by Dr. Alexandra Newton
(University of California, San Diego, CA, USA). HEK and
HeLa cells were grown in Dulbecco’s modified Eagle’s high
glucose medium (Invitrogen) containing 10% fetal bovine
serum (FBS) (Hyclone Laboratories, Logan, UT, USA) and
1% penicillin and streptomycin. SH-SY5Y cells were grown
in MEM:Ham’s F12 (1:1) (Invitrogen) containing 10% FBS,
2 mM sodium pyruvate (Invitrogen), and 1% penicillin and
streptomycin. HeLa cells were transfected using Fugene6
transfection reagent (Roche Diagnostics, Indianapolis, IN,
USA), and HEK cells were transfected with Lipofectamine
2000 transfection reagent (Invitrogen), both according to
the manufacturers’ instructions. SH-SY5Y cells were stably
transfected using Fugene HD (Roche Diagnostics) accord-
ing to the manufacturer’s instructions, with expressionconstructs for pcDNA3.1 or LRP10 variants (in pcDNA3.1)
and selected using 400 μg/ml of geneticin (G418; Invitro-
gen). For siRNA transfection of SH-SY5Y cells, 2X106 cells
were transfected with siRNA using AmaxaW NucleofectorW
Cell Line Kit V with the NucleofectorW system and pro-
gram A-023, as recommended by the manufacturer
(Amaxa, Lonza, Walkerville, MD, USA). Scrambled RNA
oligos (scramble II duplex) and LRP10 siRNA were pur-
chased from Dharmacon Research.
Immunofluorescence
Cells were seeded on coverslips. Twelve hours after trans-
fection, the cells were fixed in 3% paraformaldehyde (PFA;
Electron Microscopy Science, Hatfield, PA, USA) in
100 mM phosphate buffer (pH 7.4) for 30 min, permeabi-
lized with 0.1% Triton X-100 for 10 min, blocked with
10% goat serum for 30 min, and incubated with primary
antibodies for 1 h at RT, followed by Alexa Fluor 594- or
488-conjugated antibodies (Molecular Probes) for 1 h at
RT. The specimens were visualized using an inverted con-
focal laser-scanning microscope (FV1000, Olympus,
Tokyo, Japan) equipped with a PlanApo 60x/1.42 oil
immersion objective (Olympus). Olympus Fluoview soft-
ware version 1.6b was used to acquire and analyze the
images. The images were further processed using Adobe
Photoshop (Adobe Systems, San Jose, CA, USA).
Antibody uptake assays
HeLa cells transiently expressing APP695 and pcDNA3,
LRP10wt-HA, or LRP102DXXAA-HA, or expressing LRP10wt
or LRP102DXXAA tagged with an extracellular FLAG epitope
were grown on glass coverslips. The cells were washed
twice on ice with ice-cold DMEM. They were then incu-
bated for 60 min on ice in cold DMEM containing an
antibody against the ectodomain of APP (α-APP 22C11,
12 μg/ml) or against FLAG (2 μg/ml). Cells were then
washed, incubated at 37°C in complete medium for differ-
ent periods of time, fixed with 3% paraformaldehyde, and
processed for immunocytochemistry.
Glutathione S-transferase pull-down assays
GST fusion proteins were expressed in E. coli BL21 and
purified on glutathione-Sepharose 4B beads (Pharmacia,
Piscataway, NJ, USA) according to the manufacturer’s
instructions. 35 S-labeled in vitro translation products of
pcDNA3.1-human LRP10 were prepared using the TNT
T7 rabbit reticulocyte Quick Coupled Transcription/Trans-
lation system (Promega, San Luis Obispo, CA, USA) in the
presence of [35 S]EasyTag EXPRESS labeling mix (73% met/
22% cys; >1000 Ci/mmol, Perkin Elmer). For the pull-
down assays, GST fusion proteins (10 μg) immobilized on
glutathione-Sepharose 4B beads were incubated for 2 h at
4°C in the presence of in vitro translated products in
20 mM Tris–HCl buffer (pH 7.4) containing 150 mM
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inhibitors. The beads were washed four times in lysis buffer
and were boiled in Laemmli sample buffer. The bound pro-
teins were separated by SDS-PAGE and were detected by
autoradiography.
Biotinylation assay
SH-SY5Y cell lines stably expressing either pcDNA3,
LRP10wt, or LRP102DXXAA were washed with PBS and
were treated with membrane-impermeable sulfo-N hydro-
xysuccinimidobiotin (Pierce) in PBS for 30 min at 4°C.
The biotin labeling was quenched with 50 μl/ml of
quenching solution before the cells were lysed in buffer
(50 mM Tris buffer (pH 7.4), 150 mM NaCl, 2 mM
EDTA, 1% Triton X-100, and protease inhibitors). The
biotinylated cell surface proteins were precipitated with
NeutrAvidin Agarose (Amersham Pharmacia Biosciences)
and were analyzed by SDS-PAGE and immunoblotting.
Co-immunoprecipitation
HEK cells were plated in 60-mm culture dishes and trans-
fected with the various constructs. After 48 h, the cells
were lysed in 50 mM Tris buffer (pH 7.4) containing
150 mM NaCl, 1% NP-40, and protease inhibitors for 1 h
at 4°C and were then centrifuged at 13,000xg for 20 min.
The cleared supernatants were incubated with primary
antibodies (1 μg antibody per mg of proteins) overnight at
4°C and then with protein A-sepharose (GE Healthcare,
Piscataway, NJ, USA) or protein G-Sepharose (Zymed,
San Francisco, CA, USA) beads for 1 h. The beads were
washed three times in lysis buffer and were boiled in
Laemmli sample buffer. Bound immune complexes were
analyzed by SDS-PAGE and immunoblotting.
Immunoblotting
The protein samples were boiled in Laemmli loading buf-
fer, separated on 8% or 10% SDS-PAGE gels, and trans-
ferred to 0.45 μm pore-size nitrocellulose membranes
(Perkin Elmer, Woodbridge, ON, Canada). The mem-
branes were blocked in Tris-buffered saline (20 mM Tris–
HCl, pH 7.4, 150 mM NaCl) containing 0.1% Tween 20
and 5% nonfat dry milk and were incubated with primary
antibodies for 1 h at RT and then with horseradish
peroxidase-conjugated goat anti-rabbit or anti-mouse IgG
(Bio-Rad, Richmond, ON, Canada) for 45 min at RT and
enhanced chemiluminescence detection reagent (Pierce
Chemical, Rockford, IL, USA).
Pulse-chase labeling
For the pulse-chase experiments, the cells were incu-
bated in cysteine- and methionine-free medium (Sigma)
for 30 min prior to biolabeling using 150 μCi of L-[35 S]
cysteine and L- [35 S]methionine/ml (EasyTag EXPRESS[35 S]-labeling mix (73% met/22% cys; >1000 Ci/mmol,
Perkin Elmer)) for 5 min. The cells were then washed in ice-
cold cysteine/methionine-free medium, chased for various
time in complete medium, and lysed. Lysates were precipi-
tated with 1 μg of rabbit anti-APP pAbs (C-term.) overnight
at 4°C and were then incubated with protein A-sepharose
beads for 1 h. The beads were washed three times in lysis
buffer and prepared for standard SDS-PAGE and autoradi-
ography. Films were scanned in grayscale at a resolution of
600 dpi, and the bands were quantified using Image-Pro
Plus 6.0 (MediaCybernetics, Silver Spring, MD, USA)
APP processing products
The amount of sAPP, carboxyl-terminal fragments
(CTF), and Aβ40 products were determined by Western
blotting and/or AlphaLISA detection. AlphaLISA kits
were kindly provided by PerkinElmer (AL254 for sAPPα,
AL255 for sAPPβ, and AL275 for Aβ40). To detect sAPP
by Western blotting, 4x106 SH-SY5Y cells were seeded
on 60-mm dishes and cultured for 48 h in complete
media. The culture media was then replaced by 1.5 ml
of serum-free MEM:Ham’s F12 (1:1). After 24 h, the
conditioned medium was harvested and centrifuged at
500xg for 5 min at 4°C. Fifty μl of supernatant was
boiled with Laemmli loading buffer and directly loaded
on an SDS-PAGE gel. Immunoblotting was performed
as described above using 22C11 antibodies. The cells in
each dish in which secreted APP was collected were
lysed in 50 mM Tris buffer (pH 7.4) containing 150 mM
NaCl, 2 mM EDTA, 1% Triton X-100 and protease inhi-
bitors in order to determine and compare the amount of
cells in each dish. Ten μl of each lysates were loaded on
SDS-PAGE gels and immunoblotted for actin.
For the β-CTF Western blot analyses, 80–120 μg of
cell lysate was separated on a 16.5% Tris-Tricine gel and
transferred to a nitrocellulose membrane (0.20 μm pore
size) (350 mA for 35 min). Immunoblotting was per-
formed as described above using anti-APP C-term
antibody. For the AlphaLISA assays, cells were seeded
in 96-well plates at a density of 2x105 cells per well in
100 μl of SH-SY5Y culture media. After a 48-h incuba-
tion, the supernatants were harvested and the analytes
were quantified in triplicate using 5 μl of supernatant
per assay with an EnVision Plate Reader (PerkinElmer).
The counts were converted into pg/ml using standard
curves. The cells were lysed in 100 mM NaOH to de-
termine the total protein concentration using the BCA
method (Pierce). The total protein concentrations in
the lysates were used to normalize the concentrations
of the analytes for the various samples and clones.
Human brain tissues
Human hippocampal and frontal cortex samples from
ten autopsy-confirmed cases of AD and ten age-
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Douglas Hospital Brain Bank in Montreal, Quebec,
Canada. The mean age at death was 76.4 ± 3.1 years for
the AD patients and 71.7 ± 7.2 years for the control
group. The mean ages were not significantly different.
The postmortem interval was 22.9 ± 13.5 h for the AD
patients and 21.6 ± 8.3 h for the control group, which
was not significantly different. The AD cases had a clin-
ical diagnosis of probable AD, which was confirmed by
a neuropathological evaluation. Control cases had a
clinical diagnosis of nondemented elderly patients.
Films were scanned in grayscale at a resolution of
600 dpi, and the bands were quantified using Image-
Pro Plus 6.0 (MediaCybernetics, Silver Spring, MD,
USA).
Tissue protein extraction
Brain tissue samples (30 mg per sample) were homoge-
nized on ice in RIPA lysis buffer solution containing pro-
tease inhibitors for 10 s using a Polytron homogenizer and
were incubated on ice for 30 min. The homogenates were
centrifuged at 13,000xg for 20 min. The protein concen-
trations in the extracts were estimated using the Bradford
method (Bio-Rad), and 50 μg of protein aliquots were
stored at −80°C in Laemmli sample buffer until used. The
samples were separated on 10% SDS–PAGE gels, were
transferred to nitrocellulose membranes (0.45 μm pore
size) and were immunoblotted as described above.
Tissue RNA isolation
Total RNA was isolated from human frontal cortex tissues
(30–50 mg per sample) using the RNeasy Lipid Tissue
Mini kit (Qiagen, Toronto, ON, Canada), according to the
manufacturer’s instructions. Briefly, the tissue samples
were disrupted in Qiazol lysis reagent and homogenized
for 1 min on ice using a Polytron homogenizer until a
completely homogeneous lysate was obtained. Chloroform
was added, and the homogenate was separated into aque-
ous and organic phase by centrifugation. The upper aque-
ous phase was removed and ethanol was added to it. The
sample was then applied to an RNeasy mini spin column,
which was washed several times. In the final step, the
RNA was eluted with 50 μl of RNAse-free water. The
RNA concentration of the samples was estimated based
on A260 measurements.
Quantitative real-time RT-PCR
cDNA was synthesized using 1 μg of DNase 1 (Invitrogen)-
treated RNA and 0.5 μg of oligo(dt)12-18 primer (Invitro-
gen) and 200 U of Superscript II Reverse Transcriptase
(Invitrogen) according to manufacturer’s instructions. A
total of 25 μl of real-time RT-PCR reactions (2 μl of cDNA,
3.5 μl of 10 μM forward and reverse primers) were per-
formed using PerfeCTa SYBR Green SuperMix with LowRox (QUANTA Bioscience, Gaithersburg, MD, USA) and a
Stratagene Mx3005P QPCR System. Primers were designed
to selectively amplify human LRP10 and Ribosomal Protein
L13 (RPL13) mRNA sequences and were selected according
to the manufacturer’s guidelines. RPL13 is a good house-
keeper for qRT-PCR studies in autopsy brain tissue samples
from control and AD cases [32]. PCR primers were synthe-
sized and purified by IDT (Coralville, IA, USA). The
sequences of the PCR forward and reverse primers were





ples from five healthy and five AD patients were ana-
lyzed in duplicate. The final mRNA levels of the genes
being studied were normalized to RPL13 expression using
the comparative CT method (Stratagene) [33]. Results
are expressed as the means±SD of five independent con-
trols and five AD brain samples analyzed in duplicate for
each gene.Statistical analysis
Experiments were performed in triplicate and results are
expressed as means ± SD. The statistical significance of
differences between samples was assessed using the Stu-
dent t-test. A p< 0.01 was considered significant.Additional files
Additional file 1: Figure S1. Interaction of untagged APP with
LRP10-HA wild-type and trafficking mutant. Lysates from HEK cells
transfected with untagged APP695 and HA-pcDNA3, HA-tagged LRP10
wt
or LRP102DXXAA were immunoprecipitated with anti-HA antibody and
immunoblotted with anti-APP antibody to detect LRP10 and APP,
respectively.
Additional file 2: Figure S2. Interaction of APP and LRP10 expressed
separately and subsequently combined. HEK cells transfected
separately with either GFP or GFP-APP695 or LRP10-HA were lysed. Cell
lysates were subsequently mixed followed by immunoprecipitation with
anti-HA antibody using the same conditions as described in Figure 1.
Immunoblots with polyclonal anti-HA and anti-GFP antibodies showed a
weak post-lysis interaction between LRP10-HA and GFP-APP which
indicated that the proteins interact in vitro.
Additional file 3: Figure S3. Lower levels of AICD fragments were
detected in SH-SY5Y cells expressing high levels of LRP102DXXAA.
Western blot analysis of AICD, a co-product of β-CTF cleavage by γ-
secretase, in the cell lysates of SH-SY5Y stable clones expressing pcDNA3
vector alone (Ctl) or high levels of HA-tagged trafficking mutant
LRP102DXXAA. Actin was used as a loading control.
Additional file 4: Figure S4. LRP10 knockdown increases
amyloidogenic cleavage. LRP10-depleted cells contained higher levels
of Aβ40 and β-CTF. SH-SY5Y stable clones expressing low levels of HA-
tagged LRP10wt were transfected with control (siCTL) or LRP10 siRNA
(siLRP10) for 3 days. (A) Representative Western blots of β-CTF and LRP10
in cell lysates of the SH-SY5Y stable clones treated with control or LRP10
siRNA. Actin served as a loading control. (B) AlphaLISA quantitative
analysis of Aβ40 in the media of the LRP10 low expressor SH-SY5Y stable
clones transfected with control (siCTL) or LRP10 siRNA (siLRP10). Results
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control cells).
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